News By Tag
News By Location
Follow on Google News
Karyopharm's Xpovio (selinexor) Competetive positioning in DLBC
Karyopharm's Selinexor (Xpovio) an oral selective inhibitor of nuclear export (SINE) compound inhibiting the nuclear export protein exportin 1 (XPO1) was granted accelerated approval.
By: Mellalta Meets
Key Takeaways by Mellalta Meets
Selinexor (Xpovio) Marketing Positioning Statements
First oral therapy approved for RR DLBCL
First single agent approved in any line of DLBCL treatment
First therapy a RR DLBCL patient can take at home
Selinexor (Xpovio) Market Positioning
Selinexor (Xpovio) will be preferred as a DLBCL treatment option after two prior lines of therapy
An Estimated 9,000 DLBCL Patients Being Treated in the 3rd and 4th Line+ Setting in the U.S.
Recent FDA approvals of CAR-T therapy (2017 and 2019) and polatuzumab + bendamustine + rituximab (2019)
The approval of Karyopharm's Xpovio (selinexor) in patients with relapsed or refractory DLBCL is a huge milestone for the patients and families suffering as they have limited treatment options available for their disease.
Submit your Request for Proposals at firstname.lastname@example.org